Dapagliflozin vs Zibotentan + Dapagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03036150 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)

Result source: NCT03036150

Zibotentan + Dapagliflozin

Developed by AstraZeneca

Phase 3 in Chronic Kidney Diseasesmall molecule (combination)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06087835 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinZibotentan + Dapagliflozin
Kidney composite outcome6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150—Trial running · NCT06087835
UACR, % change-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
—Trial running · NCT06087835
eGFR slope—Not posted · NCT05998837—Trial running · NCT06087835
Haemoglobin, change—Not posted · NCT05998837—Trial running · NCT06087835

Kidney composite outcome

Dapagliflozin
6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

UACR, % change

Dapagliflozin
-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

eGFR slope

Dapagliflozin
—Not posted · NCT05998837
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

Haemoglobin, change

Dapagliflozin
—Not posted · NCT05998837
Zibotentan + Dapagliflozin
—Trial running · NCT06087835
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Dropout rate
—10 mga
NCT03036150 · Phase 3
show 10 more results
0.5%Dapagliflozin
NCT03036150 · Phase 3
5.5%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
3.2%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
17.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
20.7%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
9.9%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
—10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
—10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
2.9%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3.9%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Serious AEs
29.5%10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
8.3%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
7.9%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
12.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.6%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
1.9%10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mga
nasopharyngitis 4.3% (placebo 3.8%)
urinary tract infection 3.6% (placebo 3.7%)
hypoglycaemia 3.4% (placebo 3.3%)
NCT03036150 · Phase 3
show 9 more results
10 mg
nasopharyngitis 6.9% (placebo 4.1%)
influenza 5.5% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence
10 mg + 2.5 mg
nasopharyngitis 6.6% (placebo 4.1%)
influenza 1.3% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
10 mg
hyperkalaemia 9.1% (placebo 0%)
urinary tract infection 9.1% (placebo 0%)
fall 6.1% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
brain natriuretic peptide increased 5% (placebo 0.6%)
headache 4.5% (placebo 1.1%)
metabolic acidosis 3.9% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.25 mg
headache 6.6% (placebo 1.1%)
hypertension 5.5% (placebo 0.6%)
metabolic acidosis 5.5% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
10 mg
any adverse event 32.1% (placebo 25%)
NCT03190694 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Time to Cardio-renal Composite Endpoint 9.2% (n=2152) vs 14.5% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 197 Participants as posted
Time to Composite Renal Endpoint 6.6% (n=2152) vs 11.3% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 142 Participants as posted
Time to CV Death or HF Hospitalization 4.6% (n=2152) vs 6.4% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 100 Participants as posted
Overall Survival 4.7% vs 6.8% placebo
time to event · count
NCT03036150 · Phase 3
HbA1c -0.43% (n=140) vs -0.27% (n=145) placebo @ 24wk10 mg
absolute change · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.85% (n=151) vs -0.27% (n=145) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
UACR -22.4% (n=140) vs -1.8% (n=144) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 9 more results
-34.318% (n=28) vs 230.32% (n=3) placebo @ 12wk10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-34.318% (n=28) vs 230.32% (n=7) placebo @ 12wk10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-58.047% (n=25) vs 230.32% (n=3) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-58.047% (n=25) vs 230.32% (n=7) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-42.085% (n=23) vs 230.32% (n=3) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-42.085% (n=23) vs 230.32% (n=7) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=3) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=7) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-39.1% (n=151) vs -1.8% (n=144) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Weight -1.48% (n=144) vs -0.61% (n=148) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.65% (n=152) vs -0.61% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -13.1 vs -11.2 placebo mg @ 24wk10 mg
absolute change · mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-17.2 vs -11.2 placebo mg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
UACR 30 45% (n=144) vs 31.3% (n=148) placebo @ 24wk10 mg
responder rate · % of participants
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
57% (n=152) vs 31.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
HbA1c Less Than 7 15% (n=144) vs 10.3% (n=148) placebo @ 24wk10 mg
absolute value · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
35.1% (n=152) vs 10.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Seated SBP -6.9 vs -4.1 placebo mmHg @ 24wk10 mg
absolute change · mmHg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-8.8 vs -4.1 placebo mmHg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
eGFR -3.498 vs 6.88 placebo mL @ 12wk10 mg
absolute change · mL
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
-5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Zibotentan + Dapagliflozin's landscape